Drug Trial Radar · NCT07941544
Njinsky Ambispective Cellular Product Safety and Outcomes Registry
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 30, 2030
Study completion Dec 30, 2032
Sponsor
- Lead sponsor
- Njinsky Medical CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both as part of routine care at Njinsky Medical Centre. The registry includes separate cohorts for retinitis pigmentosa, autism spectrum disorder, female infertility conditions, and azoospermia. The retrospective component will use eligible routine-care records from 1 January 2020 through 30 November 2026. Prospective enrollment is planned from 1 December 2026 through 31 December 2030, with follow-up at 1, 3, 6, 12 and 24 months after the last treatment session. Patients may be followed by phone or in person. The study will not assign treatment or require additional tests; it will record measures obtained in routine care and information reported or documented at follow-up. Results will be described separately by condition and actual product exposure. The registry is not designed by itself to establish that a product caused a clinical outcome.
Conditions
- Retinitis Pigmentosa (RP)
- Autism Disorder
- Diminished Ovarian Reserve
- Azoospermia
- Amenorrhea Secondary
- Azoospermia, Nonobstructive
Interventions
Umbilical Cord Mesenchymal Stem CellsBiological
Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.
Stromal Vascular fractionBiological
Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with one or more adverse effects reported or documented after administrationTime frame: During observation for up to 10 hours after each administration, and at follow-up 1, 3, 6, 12, and 24 months after the participant's last session.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Njinsky Medical Centre
Lahore, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.